Effect of fenofibrate on diabetic retinopathy progression: an RCT-Only systematic review and meta-analysis incorporating the LENS trial
In brief
Fenofibrate prevents 45 cases of diabetic retinopathy progression per 1,000 patients treated
In a meta-analysis of three randomized trials (3,756 participants), fenofibrate lowered the risk of DR worsening by 23% (about 45 fewer events per 1,000) with moderate certainty. The drug did not improve visual acuity and raised the risk of venous thromboembolism. Whether these structural benefits translate into meaningful vision preservation remains uncertain.
- Journal
- Diabetes research and clinical practice (Q1)
- Published
- 4 September 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Manish Bhandari, Sandesh Devkota, Rubina Dhital, Sunil Subedi, Subodh Adhikari
- PMID
- 42697514
- DOI
- 10.1016/j.diabres.2026.113543
Why clinicians should know about it
- Picked for Internal Medicine (top studies of the week, 6 September 2026): Fenofibrate meta‑analysis for diabetic retinopathy
- Picked for Ophthalmology (top studies of the week, 6 September 2026): Meta-analysis shows fenofibrate slows DR structural progression
Abstract
Diabetic retinopathy (DR) causes preventable vision loss, yet treatments remain reactive. Fenofibrate showed ophthalmic benefits in cardiovascular trials, and LENS (2024) expanded the evidence. Under a pre-registered PRISMA 2020 protocol we searched four databases to June 25, 2026 for randomized trials of fenofibrate reporting an ophthalmic outcome in adults with diabetes, applied RoB 2 and GRADE, and pooled dichotomous outcomes as random-effects risk ratios (RR). Ten studies met inclusion criteria: six completed with extractable results and four ongoing; three completed trials contributed to the primary pooled outcome. All enrolled predominantly type 2 diabetes (one trial 26% type 1, no type-specific estimate). For DR progression, three trials (N = 3,756) gave RR 0.77 (95% CI 0.68-0.88;HKSJ 0.60-0.99; I2 0%; moderate certainty), 45 fewer events per 1,000; stratification gave 0.80 (0.68-0.93) for the LENS composite and 0.70 (0.55-0.90) for ETDRS step-based definitions (difference P = 0.37). Need for retinal treatment fell under the conventional model (RR 0.68, 0.57-0.82) but at low certainty: 90.2% of the weight came from one pre-anti-VEGF-era trial and the HKSJ interval crossed the null (0.42-1.11), so this outcome is not firm evidence about contemporary treatment need. No trial found benefit for visual acuity or function (low certainty); macular edema evidence was not combinable (very low certainty). Venous thromboembolism was increased (RR 1.52, 1.12-2.06), an estimate derived entirely from FIELD (103/4,755 vs 68/4,767). In adults with diabetes, predominantly type 2, fenofibrate slows structural DR progression but is not established as vision-preserving.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.